Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 May;53(6):1515-1523.
doi: 10.1177/03635465241260271. Epub 2025 Jan 6.

Outcomes of Revision Cartilage Restoration Surgery for Failed Primary Treatment of Chondral or Osteochondral Defects of the Knee: A Systematic Review

Affiliations
Meta-Analysis

Outcomes of Revision Cartilage Restoration Surgery for Failed Primary Treatment of Chondral or Osteochondral Defects of the Knee: A Systematic Review

Kyle N Kunze et al. Am J Sports Med. 2025 May.

Abstract

Background: Failure of primary cartilage restoration procedures of the knee that proceed to necessitating revision cartilage procedures represent a challenging clinical scenario with variable outcomes reported in previous literature.

Purpose: To perform a systematic review and meta-analysis of clinical outcomes and adverse events after revision cartilage restoration procedures of the knee for failed primary cartilage procedures.

Study design: Systematic review and meta-analysis; Level of evidence, 4.

Methods: The PubMed, OVID/MEDLINE, and Cochrane databases were queried in August 2023 for trials reporting on the outcomes of revision cartilage restoration procedures of the knee. Information pertaining to rates of failure, reoperations, graft-related complications, and patient-reported outcome measures were extracted. A meta-analysis using inverse-variance proportion models using Freeman-Tukey double-arcsine transformations and DerSimonian-Laird random-effects estimators was constructed to quantitatively describe the cumulative incidence of adverse events.

Results: Sixteen studies (1361 patients; mean age, 35.7 ± 9.3 years) were included. The most frequently performed revision cartilage procedure was autologous chondrocyte implantation (ACI; n = 755 [55.5%]). The overall rate of failure was 25.1% (95% CI, 14.4%-37.3%) at a mean 6.5 years (range, 2-26 years). The majority of studies (n = 9) reported a failure rate exceeding 20%. A significant reduction in failure was observed in favor of the revision osteochondral allograft cohort (19.0% [75/395] vs 35.7% [273/764]; relative risk, 0.63; P < .0001) compared with the revision ACI cohort. The pooled all-cause reoperation event rate was 40.8%, which ranged between 18.2% and 71.4% (13 studies). Of these studies, 12 reported reoperation rates exceeding 20%, and 7 reported rates exceeding 40%. The pooled graft-related complication event rate was 27.2%, which ranged between 5.4% and 56.6% (11 studies). Notably, all analyses demonstrated considerable or moderate heterogeneity, potentially influencing the observed variability in pooled effect estimates.

Conclusion: One of every 4 patients may experience a secondary failure after undergoing a revision cartilage procedure. Revision using an osteochondral allograft may confer a meaningful reduction in the risk of failure relative to revision using ACI. High rates of graft-related complications and reoperations are also frequently observed in this population, highlighting the challenge of treating patients with failed primary treatment of chondral or osteochondral defects of the knee.

Keywords: allograft; cartilage; chondrocyte; clinical outcomes; knee; osteochondral; revision.

PubMed Disclaimer

Conflict of interest statement

One or more of the authors has declared the following potential conflict of interest or source of funding: S.A.R. has received consulting fees from Teladoc, DJO, and Novartis Pharmaceuticals; honoraria from Flexion Therapeutics; speaking fees from Terumo and Smith + Nephew; and holds stock in Ortho RTI. He is an associate editor for AJSM. R.F.W. has received royalties from Arthrex. T.L.W. has received royalties from Stryker. R.J.W. has received consulting fees from Arthrex, JRF Ortho, and Lipogems; royalties from Arthrex and Smith + Nephew; research support from Histogenics; and holds stock or stock options in DICMD, Cymedica, Engage Surgical, Gramercy Extremity Orthopedics, Pristine Surgical, and RecoverX. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.

Similar articles

LinkOut - more resources